TWI873094B - Compositions for inhibiting proliferation of cancer cells, anticancer compositions, compositions for inhibiting canceration of normal cells, compositions for inhibiting the onset of cancer, and compositions for inducing cancer cell death - Google Patents

Abstract

The subject of the present invention is to inhibit the canceration of cells and the deterioration of cancer, i.e. the onset of cancer, or to induce cell death of cancer cells. The present invention provides a composition for inhibiting the proliferation of cancer cells, an anti-cancer composition, a composition for inhibiting the canceration of normal cells, a composition for inhibiting the onset of cancer, and a composition for inducing cancer cell death, which contains at least one of curcuminol A and curcuminol B as an effective ingredient.

Description

Compositions for inhibiting proliferation of cancer cells, anticancer compositions, compositions for inhibiting canceration of normal cells, compositions for inhibiting the onset of cancer, and compositions for inducing cancer cell death

The present invention relates to a composition for inhibiting the proliferation of cancer cells, an anti-cancer composition, a composition for inhibiting the canceration of normal cells, a composition for inhibiting the onset of cancer, and a composition for inducing cancer cell death.

The process of death from cancer has been analyzed in detail and gradually clarified. Currently, a process of cancer development called multi-stage carcinogenesis is proposed, which refers to the accumulation of abnormalities in cells, which lead to gene damage due to exposure to chemicals, radiation, and viruses, and mutations in multiple genes such as oncogenes or tumor suppressor genes. After acquiring various abnormal properties such as cell proliferation, the cancer acquires the ability to invade, metastasize, and relapse, and its malignancy further increases (malignant development) and leads to death. Therefore, it is believed that inhibiting cell carcinogenesis caused by chemical, radiation, and virus-induced gene mutations is more important for preventing cancer, while inhibiting the proliferation, infiltration, and metastasis of cancer cells is more important for inhibiting the progression of cancer malignancy.

Patent document 1 describes an anti-tumor agent having a protein-bound polysaccharide isolated from the rhizome of turmeric as an active ingredient.

On the other hand, turmeronol A and turmeronol B are known components isolated from turmeric and their structures have been determined (non-patent document 1). Non-patent document 1 reports that turmeronol A has the effect of inhibiting the enzymatic activity of soybean lipoxygenase and has an antioxidant effect. [Prior technical document] [Patent document]

Patent document 1: Japanese Patent Publication No. 60-67428 [Non-patent document]

Non-patent literature 1: Agric Biol Chem. 1990; 54 (9): 2367-71

[The problem the invention is trying to solve]

Patent document 1 describes the effects of protein-bound polysaccharides isolated from the rhizome of turmeric, and non-patent document 1 describes the antioxidant effects of turmeric flavonol A. However, these documents do not describe the effects of turmeric flavonol A and turmeric flavonol B derived from turmeric on inhibiting cell carcinogenesis and cancer metastasis, i.e., the onset of cancer, or inducing cancer cell death.

Therefore, the present invention provides a method for inhibiting the canceration of cells and the deterioration of cancer, i.e. the onset of cancer, or a method for inducing cancer cell death. [Technical means for solving the problem]

The inventors of the present invention have found that curcuminol A and curcuminol B can inhibit the carcinogenesis of cells and the deterioration of cancer, i.e. the onset of cancer, or can induce cancer cell death, thereby completing the following present invention. (1) A composition for inhibiting the proliferation of cancer cells, which contains at least one of curcuminol A and curcuminol B as an active ingredient. (2) A composition for inhibiting the proliferation of cancer cells as described in (1), wherein the cancer cells are colorectal cancer cells. (3) An anticancer composition, which contains at least one of curcuminol A and curcuminol B as an active ingredient. (4) The anticancer composition as described in (3), which is an anticancer composition for colorectal cancer. (5) A composition for inhibiting the carcinogenesis of normal cells, which contains at least one of curcuminol A and curcuminol B as an active ingredient. (6) A composition for inhibiting the carcinogenesis of normal cells as described in (5), which inhibits the carcinogenesis of normal cells into colorectal cancer. (7) A composition for inhibiting the onset of cancer, which contains at least one of curcuminol A and curcuminol B as an active ingredient. (8) A composition for inhibiting the onset of cancer as described in (7), which is a composition for inhibiting the onset of cancer for colorectal cancer. (9) A composition for inducing cancer cell death, which contains at least one of curcuminol A and curcuminol B as an active ingredient. (10) The cancer cell death-inducing composition as described in (9), wherein the cancer cells are colorectal cancer cells.

(11) A use of at least one of turmeric flavonol A and turmeric flavonol B, wherein at least one of turmeric flavonol A and turmeric flavonol B is used to produce a composition for inhibiting the proliferation of cancer cells. (12) A use of at least one of turmeric flavonol A and turmeric flavonol B, wherein at least one of turmeric flavonol A and turmeric flavonol B is used to produce a drug for inhibiting the proliferation of cancer cells. (13) A method for inhibiting the proliferation of cancer cells, comprising: administering at least one of turmeric flavonol A and turmeric flavonol B to cancer cells in vivo or in vitro; and inhibiting the proliferation of the above cancer cells. (14) A turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B, which is used to inhibit the proliferation of cancer cells in vivo or in vitro. (15) The use described in (11), the use described in (12), the method described in (13), or the turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B described in (14), wherein the cancer cells are colorectal cancer cells.

(16) A use of at least one of turmeric flavonol A and turmeric flavonol B, which is to use at least one of turmeric flavonol A and turmeric flavonol B to prepare an anti-cancer composition. (17) A use of at least one of turmeric flavonol A and turmeric flavonol B, which is to use at least one of turmeric flavonol A and turmeric flavonol B to prepare an anti-cancer drug. (18) A method for treating cancer, comprising: Administering at least one of turmeric flavonol A and turmeric flavonol B to a patient in need of cancer treatment; and Treatment of cancer in the above patient. (19) A turmericflavonol A, turmericflavonol B, or a mixture of turmericflavonol A and turmericflavonol B, which is used to treat cancer in a patient in need of cancer treatment. (20) The use described in (16), the use described in (17), the method described in (18), or the turmericflavonol A, turmericflavonol B, or a mixture of turmericflavonol A and turmericflavonol B described in (19), wherein the above-mentioned cancer is colorectal cancer.

(21) A use of at least one of turmeric flavonol A and turmeric flavonol B, wherein at least one of turmeric flavonol A and turmeric flavonol B is used to produce a composition for inhibiting the carcinogenesis of normal cells. (22) A use of at least one of turmeric flavonol A and turmeric flavonol B, wherein at least one of turmeric flavonol A and turmeric flavonol B is used to produce a drug for inhibiting the carcinogenesis of normal cells. (23) A method for inhibiting the carcinogenesis of normal cells, comprising: administering at least one of turmeric flavonol A and turmeric flavonol B to normal cells in vivo or in vitro; and inhibiting the carcinogenesis of the above normal cells. (24) A turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B, which is used to inhibit the carcinogenesis of normal cells in vivo or in vitro. (25) The use described in (21), the use described in (22), the method described in (23), or the turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B described in (24), wherein the above-mentioned carcinogenesis is carcinogenesis of colorectal cancer.

(26) A use of at least one of turmeric flavonol A and turmeric flavonol B, which is to use at least one of turmeric flavonol A and turmeric flavonol B to produce a composition for inhibiting the onset of cancer. (27) A use of at least one of turmeric flavonol A and turmeric flavonol B, which is to use at least one of turmeric flavonol A and turmeric flavonol B to produce a drug for inhibiting the onset of cancer. (28) A method for inhibiting the onset of cancer, comprising: Administering at least one of turmeric flavonol A and turmeric flavonol B to a patient who needs to inhibit the onset of cancer; and Inhibiting the onset of cancer in the above patient. (29) A turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B, which is used to inhibit the onset of cancer in a patient in need of inhibiting the onset of cancer. (30) The use described in (26), the use described in (27), the method described in (28), or the turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B described in (29), wherein the above-mentioned cancer is colorectal cancer.

(31) A use of at least one of turmeric flavonol A and turmeric flavonol B, wherein at least one of turmeric flavonol A and turmeric flavonol B is used to produce a composition for inducing cancer cell death. (32) A use of at least one of turmeric flavonol A and turmeric flavonol B, wherein at least one of turmeric flavonol A and turmeric flavonol B is used to produce a drug for inducing cancer cell death. (33) A method for inducing cell death of cancer cells, comprising: administering at least one of turmeric flavonol A and turmeric flavonol B to cancer cells in vivo or in vitro; and inducing cell death of the above cancer cells. (34) A turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B, which is used to induce cell death of cancer cells in vivo or in vitro. (35) The use described in (31), the use described in (32), the method described in (33), or the turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B described in (34), wherein the cancer cells are colorectal cancer cells.

This specification contains the disclosure contents of Japanese Patent Application No. 2018-093848, which is the basis for the priority of this application. [Effect of the invention]

The present invention provides a composition for inhibiting the proliferation of cancer cells, an anti-cancer composition, a composition for inhibiting the cancerization of normal cells, a composition for inhibiting the onset of cancer, and a composition for inducing cancer cell death, which contains at least one of curcuminol A and curcuminol B as an active ingredient.

<Active ingredients> Turmeric flavonol A and turmeric flavonol B are compounds with the following planar structures.

[Chemistry 1]

[Chemistry 2]

As is well known, the stereo configuration of natural turmeric flavonol A and turmeric flavonol B separated from turmeric is S-type at the carbon 6 position in the partial structure of 2-methyl-2-heptene-4-one. However, the turmeric flavonol A and turmeric flavonol B that can be used in the present invention can be any turmeric flavonol A and turmeric flavonol B as long as they have the above-mentioned planar structure, and are not limited to the turmeric flavonol A and turmeric flavonol B derived from the stereo structure of turmeric, and preferably the turmeric flavonol A and turmeric flavonol B derived from the stereo structure of turmeric. In the present invention, turmeric flavonol A and turmeric flavonol B in various forms such as salts and hydrates can be used. The salt form of curcuminol A and curcuminol B is not particularly limited as long as it is a pharmaceutically acceptable salt, and an example thereof is sodium salt (sodium salt of phenolic hydroxyl group).

In each aspect of the present invention, the active ingredient is at least one of turmeric flavonol A and turmeric flavonol B. That is, the active ingredient may be composed of only turmeric flavonol A, may be composed of only turmeric flavonol B, or may be a mixture of turmeric flavonol A and turmeric flavonol B.

The active ingredients used in the present invention may be derived from plants or may be artificially synthesized. For example, optically active (+)-curcuminol A can be synthesized by the method described in Biosci Biotechnol Biochem. 1993; 57(7): 1137-40.

The active ingredients used in the present invention are preferably derived from plant materials, and more preferably from plants of the genus Curcuma in the family Curcumae. Examples of plants of the genus Curcuma in the family Curcumae include Curcuma longa, Curcuma aromatica, Curcuma zedoaria, Curcuma phaeocaulis, Curcuma kwangsiensis, Curcuma wenyujin, and Curcuma xanthorrhiza, and Curcuma longa is particularly preferred. Curcuma flavonol A and curcuma flavonol B can be obtained from the rhizome and other parts of plants of the genus Curcuma in the family Curcumae. The rhizomes may be collected from the soil, or the appropriate parts of the rhizomes may be kept in their original form, or cut into appropriate sizes or shapes, or made into a powdered form. The plant material may also be suitably dried.

At least one compound selected from curcuminol A and curcuminol B used in the present invention may be in any form, such as a plant or plant processed product containing the compound, an extract extracted from the plant or plant processed product, a fraction prepared from the extract with improved purity of the compound, or a compound isolated from the extract or fraction.

As an extraction solvent used in the preparation of an extract containing at least one selected from turmeric flavonol A and turmeric flavonol B derived from plants or plant processed products, at least one selected from the group consisting of water, polar organic solvents and non-polar organic solvents, or a supercritical fluid such as supercritical carbon dioxide can be exemplified. As at least one extraction solvent selected from the group consisting of water, polar organic solvents and non-polar organic solvents, water, polar organic solvents, mixed solvents of water and polar organic solvents, non-polar organic solvents, etc. can be listed. The polar organic solvent can also be a mixed solvent of a plurality of polar organic solvents. The non-polar organic solvent may also be a mixed solvent of a plurality of non-polar organic solvents. The so-called "water" also includes hot water. As hot water, for example, hot water above 95°C may be used. As the polar organic solvent, at least one alcohol (or a mixed solvent of a plurality of alcohols) may be cited. As the alcohol, there is no particular limitation, and methanol and ethanol are preferred. When a mixed solvent of alcohol and water is used as an extraction solvent, the mixing ratio is not particularly limited. For example, the weight ratio is preferably in the range of 10:90 to 90:10, and more preferably in the range of 20:80 to 50:50. The extraction method of at least one of turmeric flavonol A and turmeric flavonol B selected from plants or plant processed products is not particularly limited. The extract containing at least one selected from turmeric flavonol A and turmeric flavonol B is used after the extraction solvent is evaporated and removed as needed.

The method for preparing a fraction having a higher purity of at least one compound selected from turmeric flavonol A and turmeric flavonol B from the extract is not particularly limited, and examples thereof include: subjecting the extract containing at least one compound selected from turmeric flavonol A and turmeric flavonol B to liquid-liquid separation of ethyl acetate/water, and purifying the compound to a higher degree in ethyl acetate fractionation; and subjecting the extract or fraction to a chromatography method such as column chromatography to purify the compound to a higher degree. As the chromatography method, reverse phase column chromatography, normal phase thin layer chromatography, etc. can be used.

The method for isolating at least one compound selected from curcuminol A and curcuminol B from the extract or fraction is not particularly limited, and a method for isolating the compound by chromatography or the like can be used.

At least one compound selected from curcuminol A and curcuminol B, a plant or plant processed product containing the above compound, or an extract or fraction of a plant or plant processed product containing the above compound can also be processed by drying, powdering, granulating, solubilizing, etc. by conventional methods.

<Composition for inhibiting proliferation of cancer cells, anti-cancer composition, composition for inhibiting canceration of normal cells, composition for inhibiting the onset of cancer, composition for inducing cancer cell death> The first aspect of the present invention is a composition for inhibiting proliferation of cancer cells, which contains at least one selected from turmeric flavonol A and turmeric flavonol B as an active ingredient. The composition for inhibiting proliferation of cancer cells of the present invention is preferably a composition for inhibiting proliferation of colorectal cancer cells. In addition, the first aspect of the present invention is a use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a composition for inhibiting proliferation of cancer cells. Furthermore, the first aspect of the present invention is related to a use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a drug for inhibiting the proliferation of cancer cells. Furthermore, the first aspect of the present invention is related to a method for inhibiting the proliferation of cancer cells, which comprises: administering at least one selected from turmeric flavonol A and turmeric flavonol B to cancer cells in vivo or in vitro; and inhibiting the proliferation of the above cancer cells. Furthermore, the first aspect of the present invention is related to a turmeric flavonol A, turmeric flavonol B, or a mixture of turmeric flavonol A and turmeric flavonol B, which is used to inhibit the proliferation of cancer cells in vivo or in vitro.

The second aspect of the present invention is related to an anticancer composition, which contains at least one selected from turmeric flavonol A and turmeric flavonol B as an active ingredient. The anticancer composition of the present invention is preferably an anticancer composition for colorectal cancer. In addition, the second aspect of the present invention is related to the use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to prepare an anticancer composition. In addition, the second aspect of the present invention is related to the use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to prepare an anticancer drug. In addition, the second aspect of the present invention is related to a method for treating cancer, comprising: administering at least one selected from turmeric flavonol A and turmeric flavonol B to a patient in need of cancer treatment; and treating cancer in the patient. In addition, the second aspect of the present invention is related to at least one selected from turmeric flavonol A and turmeric flavonol B, which is used to treat cancer in a patient in need of cancer treatment.

The third aspect of the present invention is a composition for inhibiting the canceration of normal cells, which contains at least one selected from turmeric flavonol A and turmeric flavonol B as an active ingredient. The composition for inhibiting the canceration of normal cells of the present invention is preferably used to inhibit the canceration of normal cells into colorectal cancer. In addition, the third aspect of the present invention is a use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a composition for inhibiting the canceration of normal cells. Furthermore, the third aspect of the present invention is related to a use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a drug for inhibiting the canceration of normal cells. Furthermore, the third aspect of the present invention is related to a method for inhibiting the canceration of normal cells, which comprises: administering at least one selected from turmeric flavonol A and turmeric flavonol B to normal cells in vivo or in vitro; and inhibiting the canceration of the above normal cells. Furthermore, the third aspect of the present invention is related to at least one selected from turmeric flavonol A and turmeric flavonol B, which is used to inhibit the canceration of normal cells in vivo or in vitro.

The fourth aspect of the present invention is related to a composition for inhibiting the onset of cancer, which contains at least one selected from turmeric flavonol A and turmeric flavonol B as an active ingredient. The composition for inhibiting the onset of cancer of the present invention is preferably a composition for inhibiting the onset of cancer for colorectal cancer. In addition, the fourth aspect of the present invention is related to the use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a composition for inhibiting the onset of cancer. In addition, the fourth aspect of the present invention is related to the use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a medicine for inhibiting the onset of cancer. In addition, the fourth aspect of the present invention is related to a method for inhibiting the onset of cancer, which comprises: administering at least one selected from turmeric flavonol A and turmeric flavonol B to a patient in need of inhibiting the onset of cancer; and inhibiting the onset of cancer in the patient. In addition, the fourth aspect of the present invention is related to at least one selected from turmeric flavonol A and turmeric flavonol B, which is used to inhibit the onset of cancer in a patient in need of inhibiting the onset of cancer.

The fifth aspect of the present invention is related to a cancer cell death-inducing composition, which contains at least one selected from turmeric flavonol A and turmeric flavonol B as an active ingredient. The cancer cell death-inducing composition of the present invention is preferably a cell death-inducing composition for colorectal cancer cells. In addition, the fifth aspect of the present invention is related to a use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a cancer cell death-inducing composition. Furthermore, the fifth aspect of the present invention is related to a use of at least one selected from turmeric flavonol A and turmeric flavonol B, which is to use at least one selected from turmeric flavonol A and turmeric flavonol B to produce a drug for inducing cancer cell death. Furthermore, the fifth aspect of the present invention is related to a method for inducing cell death of cancer cells, which comprises: administering at least one selected from turmeric flavonol A and turmeric flavonol B to cancer cells in vivo or in vitro; and inducing cell death of the above cancer cells. Furthermore, the fifth aspect of the present invention is related to at least one selected from turmeric flavonol A and turmeric flavonol B, which is used to induce cell death of cancer cells in vivo or in vitro.

The above-mentioned active ingredients or compositions or drugs containing the same used in the present invention may be compositions in various forms such as pharmaceuticals, beverages, feeds, food additives, feed additives, etc., and are more preferably pharmaceuticals or beverages. Beverages also include functional foods, specific health foods, and supplements for nutritional supplements. The compositions or drugs containing the above-mentioned active ingredients used in the present invention are preferably in the form of compositions that are taken orally or nasally, and are more preferably in the form of compositions that are taken orally.

The composition or medicine containing the above-mentioned compound in one embodiment of the present invention preferably contains at least one selected from turmeric flavonol A and turmeric flavonol B in a daily intake or administration amount for one person, especially for one adult, such that the total amount of turmeric flavonol A and turmeric flavonol B is 100 μg or more. In another embodiment of the present invention, the composition or medicine containing the above-mentioned active ingredient is preferably taken or administered in a daily amount for one person, especially for one adult, such that turmeric flavonol A becomes 80 μg or more and/or turmeric flavonol B becomes 20 μg or more, and more preferably, turmeric flavonol A becomes 80 μg or more and turmeric flavonol B becomes 20 μg or more, and contains at least one selected from turmeric flavonol A and turmeric flavonol B. According to these embodiments, cancer cell proliferation inhibition, anti-cancer effect, normal cell cancerization inhibition, cancer pathogenesis inhibition, or cancer cell death induction effect can be effectively obtained. The "daily intake or administration amount" referred to herein refers to the amount of the composition of the present invention, typically 0.1 g to 500 g, when taken or administered orally or nasally, preferably orally. The above-mentioned active ingredient or the composition or medicine containing the same used in the present invention can be taken or administered continuously or when necessary.

The above-mentioned active ingredient or the composition or medicine containing the same used in the present invention may be the above-mentioned active ingredient itself, or may be a composition containing the above-mentioned active ingredient and at least one other ingredient. When the above-mentioned active ingredient or the composition or medicine containing the same used in the present invention contains the above-mentioned active ingredient and at least one other ingredient, it may be a composition in which the above-mentioned active ingredient and at least one other ingredient are mixed, it may be a composition in which the above-mentioned active ingredient and at least one other ingredient are formulated by an appropriate method, or it may be a composition in which the above-mentioned active ingredient and at least one other ingredient are formulated and then mixed with other ingredients.

The shape of the active ingredient or the composition or medicine containing the active ingredient used in the present invention is not particularly limited, and may be in any shape such as liquid, fluid, gel, semi-solid, or solid.

The at least one other ingredient that can be contained in the above-mentioned active ingredient or the composition or medicine containing the same used in the present invention is not particularly limited, and preferably includes ingredients that are permitted in the final form of medicines, drinks, feeds, food additives, feed additives, etc. and can be orally ingested.

Examples of such other ingredients include sweeteners, acidulants, vitamins, minerals, thickeners, emulsifiers, antioxidants, water, etc. Furthermore, pigments, flavorings, preservatives, antiseptics, anti-mold agents, and other physiologically active substances may be added as needed.

As sweeteners, there may be mentioned monosaccharides or disaccharides such as glucose, fructose, sucrose, lactose, maltose, palatinose, trehalose, and xylose, isomerized sugars (glucose-fructose syrup, fructose-glucose syrup, mixed isomerized sugars of granulated sugar, etc.), sugar alcohols (erythritol, xylitol, lactitol, isomalt, sorbitol, reduced syrup, etc.), honey, and high-intensity sweeteners (sucralose, acesulfame potassium, thaumatin, stevia, aspartame, etc.), etc.

As the acidulant, there are citric acid, apple acid, gluconic acid, tartaric acid, lactic acid, phosphoric acid, or salts thereof, and one or more of them can be used.

As vitamins, there are vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin E, niacin, inositol, etc.

Minerals include calcium, magnesium, zinc, iron, etc.

As thickeners, carrageenan, gellan gum, samson gum, gum arabic, tamarind gum, guar gum, locust bean gum, karaya gum, agar, gelatin, pectin, soybean polysaccharides, carboxymethyl cellulose (CMC), etc. can be listed.

As emulsifiers, there can be mentioned glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, lecithin, plant sterols, saponins, and the like.

As antioxidants, vitamin C, tocopherol (vitamin E), enzyme-modified rutin, catechins, etc. can be listed.

The above-mentioned other ingredients can be appropriately formulated in amounts within the ranges commonly used by the industry in compositions such as beverages and pharmaceuticals.

The composition or medicine prepared by preparing the above-mentioned active ingredient and at least one other ingredient in the present invention by an appropriate method can be in the form of solid compositions such as powder, granules, capsules, tablets (including coated tablets such as sugar-coated tablets or multi-layer tablets, orally disintegrating tablets, chewable tablets, etc.), or in the form of liquid compositions such as solutions. [Examples]

1. Evaluation of anticancer effect Tumeronol A and Tumeronol B (both commercially available from Nagara Science Co., Ltd.) were dissolved in dimethyl sulfoxide and used in the following test.

HT-29 cells, a cell line of human colorectal cancer, were suspended in RPMI1640 medium (containing 10% FBS (Fetal Bovine Serum)), seeded in a 96-well microplate at a cell number of 3.0×10 ³ per well, and cultured for 24 hours at 37°C and 5% CO _2. The HT-29 cells cultured in the 96-well plate were cultured for 72 hours in RPMI1640 medium (containing 2.5% FBS) containing either 12.5 μM, 25 μM, 50 μM, or 100 μM of turmeric flavonol A or turmeric flavonol B. WST-1 reagent was added 2 hours before the end of the culture, and the absorbance (cell metabolic activity) was measured with a plate reader 2 hours later. The metabolic activity of HT-29 cells cultured in the same manner except that RPMI1640 medium without the sample (curcuminol A, curcuminol B) was set as 100%, and the change rate of metabolic activity of HT-29 cells cultured in RPMI1640 medium containing the sample at each concentration was calculated. The cell metabolic activity here refers to the cell proliferation activity and the over-activated life-sustaining activity.

The results related to turmeric flavonol A are shown in FIG1 , and the results related to turmeric flavonol B are shown in FIG2 . FIG1 shows that by treating HT-29 cells with turmeric flavonol A, the metabolic activity of the cells is significantly reduced in a dose-dependent manner. Similarly, FIG2 shows that by treating HT-29 cells with turmeric flavonol B, the metabolic activity of the cells is significantly reduced in a dose-dependent manner. These results show that both turmeric flavonol A and turmeric flavonol B inhibit the metabolic activity of colorectal cancer cells. The inhibition of the metabolic activity of cancer cells here refers to the inhibition of cancer cell proliferation, inhibition of cancerization, and induction of cancer cell death.

All publications, patents, and patent applications cited in this specification are directly incorporated into this specification by reference.

Figure 1 shows the results of the determination of the inhibitory ability of tumeronol A on the metabolic activity of HT-29 cells, which is a cell line of human colorectal cancer. Figure 2 shows the results of the determination of the inhibitory ability of tumeronol B on the metabolic activity of HT-29 cells.

Claims (5)

A use of at least one of turmeric flavonol A and turmeric flavonol B for preparing a composition for inhibiting the proliferation of colorectal cancer cells. A use of at least one of turmeric flavonol A and turmeric flavonol B for preparing an anticancer composition for colorectal cancer. A use of at least one of turmeric flavonol A and turmeric flavonol B for preparing a composition for inhibiting the transformation of normal cells into colorectal cancer. A use of at least one of turmeric flavonol A and turmeric flavonol B for preparing a composition for inhibiting the onset of colorectal cancer. A use of at least one of turmeric flavonol A and turmeric flavonol B for preparing a composition for inducing colorectal cancer cell death.